Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan Conditioning in Pediatric Allo-HSCT
NCT02333058Phase 2Completed
- Sponsor
- medac GmbH
- Start
- Nov 2014
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more, sponsored by medac GmbH. Primary endpoint: Freedom from Transplant-Related Mortality. Started Nov 2014; status: completed.
02
Drugs
treosulfan
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT02333058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333058.